Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06769126 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT06769126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06769126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
November 6, 2025
Completion date
December 31, 2029
Enrollment
900 (estimated)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage lung small cell carcinoma, lung small cell carcinoma, a subtype, lung small cell carcinoma, i subtype, lung small cell carcinoma, n subtype, lung small cell carcinoma, p subtype